Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS
Clinical neuropharmacology · 21 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Neurological Disorders and Stroke
- Gobierno
- National Center for Research Resources
- Gobierno
- NCRR NIH HHS
- Gobierno
- NINDS NIH HHS
- Subvenciones
- National Center for Research Resources (UL1 RR 025758); National Institute of Neurological Disorders and Stroke (U10 NS044482)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2015-09-01 · Clin Neuropharmacol · vol. 38 · número 5 · págs. 163–169
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 29 citas · más que el 92% de estudios similares · 2.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 21 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Coffee research and impacts · Parkinson's Disease Mechanisms and Treatments · Folate and B Vitamins Research
- Palabras clave
- Caffeine, Medicine, Parkinson's disease, Disease, Neuroscience, Psychology, Internal medicine
- MeSH
- humans, parkinson disease, disease progression, creatine, caffeine, central nervous system stimulants, drug interactions, middle aged, female, male
13 autores
- David K. Simon🇺🇸 · autor de correspondenciaBeth Israel Deaconess Medical Center; Harvard University; University of Rochester Medicine; University of Colorado Anschutz
- Cai Wu🇺🇸University of Miami; The University of Texas Health Science Center at Houston
- Barbara C. Tilley🇺🇸University of Miami; The University of Texas Health Science Center at Houston
- Anne-Marie A. Wills🇺🇸San Francisco VA Medical Center; Harvard University; Massachusetts General Hospital
- Michael J. Aminoff🇺🇸University of California, San Francisco; Parkinson's and Movement Disorder Institute
- Jacquelyn L. Bainbridge🇸🇬🇺🇸Singapore General Hospital; University of Colorado Anschutz; University of Montana
- Robert A. Hauser🇺🇸University of South Florida
- Jay S. Schneider🇺🇸Thomas Jefferson University
- Saloni Sharma🇺🇸 · autor de correspondenciaBeth Israel Deaconess Medical Center; Harvard University; University of Rochester Medicine
- Carlos Singer🇺🇸University of Miami; The University of Texas Health Science Center at Houston
- Caroline M. Tanner🇺🇸San Francisco VA Medical Center; Harvard University; University of California, San Francisco; Massachusetts General Hospital; Parkinson's and Movement Disorder Institute
- Daniel Dung Truong🇺🇸University of California, San Francisco; Parkinson's and Movement Disorder Institute
- Pei Shieen Wong🇸🇬🇺🇸Singapore General Hospital; University of Colorado Anschutz; University of Montana
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.
Methods
Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified Parkinson Disease Rating Scale score and the interaction of this association with creatine intake were assessed.
Results
Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine.
Conclusions
This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.